JPMorgan lowered the firm’s price target on U.S. Physical Therapy (USPH) to $110 from $120 and keeps an Overweight rating on the shares. Following Q4 earnings, the firm is updating its estimates, noting that for 2025 it increased its revenue estimate to $747M while bringing down its adjusted EBITDA estimate to $91M. For 2026, the firm increased its revenue estimate to $794M while maintaining its adjusted EBITDA estimate at $101M, the analyst added.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on USPH:
- US Physical Therapy Acquires Wyoming Clinics for Expansion
- U.S. Physical Therapy acquires three-clinic physical therapy practice in Wyoming
- U.S. Physical Therapy price target lowered to $98 from $108 at Barrington
- U.S. Physical Therapy: Strong Financials and Strategic Growth Drive Buy Rating
- U.S. Physical Therapy Reports Strong 2024 Results